Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
“In the primary endpoint of PFS, Enhertu monotherapy significantly reduced the risk of disease progression or death by 37.0% versus pembrolizumab plus chemotherapy (hazard ratio [HR] 0.63; 95% confidence interval [CI] 0.50-0.79; p<0.0001). Median PFS was 14.3 months with Enhertu compared to 8.3 months for pembrolizumab plus chemotherapy as assessed by blinded independent central review (BICR).”
New lung cancer drug lifts survival versus chemotherapy
“Patients treated with gotistobart lived for a median 18.5 months, compared with 10 months for those given the standard-of-care chemotherapy, BioNTech said in a release this week. The updated results are from a late-stage study evaluating patients with metastatic squamous non-small cell lung cancer whose disease progressed when they were undergoing prior immunotherapy and chemotherapy.”
Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer
“Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.”
Tagrisso Shows 8-Year Survival Benefit in EGFR-Mutated Lung Cancer
“Eight-year landmark OS improved with adjuvant osimertinib: 74% vs 58% in stage II–IIIA, and 79% vs 64% across stage IB–IIIA, with ~47%–48% relative death-risk reduction. Survival separation persisted despite substantial crossover to osimertinib after recurrence in the placebo arm, a design feature that typically attenuates OS differences between randomized groups.”
AI tool successfully predicts outcomes of immunotherapy in lung cancer
“Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine. The study reported findings from the I3LUNG project, a large international trial aimed at improving the treatment of metastatic NSCLC by developing AI-based predictive models that can help determine the best therapeutic approach for each individual.”
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
“Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroups. Among patients who received IBTROZI after prior chemotherapy, response rates remained consistent, offering reassurance for patients who begin chemotherapy before a ROS1 fusion is identified.”
GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
“94% objective response rate at 15.2 months follow-up. 90% of patients were progression free at 12 months, with median PFS rate still to be reached. 70% of patients with measurable brain metastases achieved complete clearance of detectable brain tumours. Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026.”
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
“On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.”
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
“GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate (ADC) as a threat to Amgen and Merck & Co. in the lung cancer field.”
Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial
“Topotecan has been the default second-line chemotherapy for relapsed small-cell lung cancer for decades, and its survival benefit in that setting is modest at best. Against that backdrop, interim data from the randomized phase III TAISHAN-302 trial show that Tam-Peli (tambotatug pelitecan, YL201) cut the risk of death compared with topotecan in Chinese patients whose disease progressed after platinum-based chemotherapy, with or without a PD-L1 inhibitor.”
Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer
“Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).”
SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026
“New global Phase 1 data from a randomized dose-expansion cohort of iza-bren in previously treated EGFR-mutated metastatic NSCLC demonstrate promising antitumor activity and a tolerable safety profile, supporting selection of 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose.”
Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
“(SEOUL, Republic of Korea — Saturday, September 12th 6:15 p.m. Standard Time) — Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.”
Pancreatic cancer drug may also help fight treatment-resistant lung cancer
“An experimental treatment may offer a new option for people with advanced lung cancer linked to RAS mutations. The Food and Drug Administration (FDA) recently approved daraxonrasib (Rasonque) for certain people with metastatic pancreatic cancer, but researchers are also studying it for lung cancer. In an early-stage trial, tumors shrank in more than 30% of participants who received the drug. In a smaller subgroup, tumors shrank in 42% of participants, although researchers need a controlled trial to confirm the drug’s benefits.”
CDI-Led Team Awarded $3.7M NIH Grant to Boost Lung Cancer Screening
“Key Takeaways: Witness Project® Lung is a five-year research initiative focused on increasing lung cancer screening among eligible African Americans. The project received a $3.7 million grant from the National Cancer Institute and runs through June 2031. The program uses personal stories from trained community members and guidance from Lay Health Advisors to encourage screening. Researchers are working with 22 churches and community organizations across northern New Jersey and the New York City area. The research is led by Hackensack Meridian Center for Discovery and Innovation with partners from Memorial Sloan Kettering Cancer Center and the Icahn School of Medicine at Mount Sinai.”
Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent
“Precision MRI with hProCA32.Collagen enables early, noninvasive detection and quantification of lung tumors and metastases with improved contrast, outperforming CT and standard MRI. This is a demonstration of simultaneous MRI detection of primary tumors and metastases in the lung and adrenal glands, with collagen mapping. This approach offers a radiation-free tool for early diagnosis, staging, and monitoring in LUAD.”
Cancer’s protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells
“The study, published in the journal Molecular Cancer, demonstrates for the first time that SCLC tumor cells rely on the nonsense-mediated mRNA decay (NMD) pathway to cope with their extremely high mutation burden. This mechanism enables tumor cells to break down harmful mutated products, thereby ensuring their survival; at the same time, however, it makes them vulnerable to new therapeutic approaches.”
